Mabion S.A. — Capital/Financing Update 2020

May 19, 2020

Subject matter:Decision on the intention to issueU series ordinary bearer shares of the Company in order toincreasethe share capitalof Mabion S.A.

The Management Board of Mabion S.A. ("Company")informs that today it made a decision on the intention to issue up to1,907,281 U series ordinary bearer shares of the Company with a nominalvalue of PLN 0.10 each, to increase the Company's share capital by anamount not lower than PLN 0.10 and not higher than PLN 190,728.10. Theabove decision was also approved by the Company's Supervisory Boardtoday.

With regard to the above, the Company will propose anitem on the agenda of the next Ordinary General Meeting of the Company,providing for the adoption of a resolution on increasing the Company'sshare capital by issue of U series ordinary bearer shares.

The aim of the planned issue is to obtain additionalfunding for working capital and, in particular, to accelerate theongoing development of MabionCD20 and to achieve the milestonesenvisaged to submit an application for marketing authorisation forMabionCD20 to the European Medicines Agency as soon as possible. Inaddition, the company continues the required development activities toobtain registration in the US.

The acquired capital will allow Mabion, a fullyintegrated company with GMP-certified facilities, to conduct furtherdevelopment based on its previous experience, robust quality process,experienced and qualified workforce, as well as technological capacity.

The intention of the Company's Management Board isthat the issue is effected in the form of a private placement within themeaning of Art. 431 §2 (1) of the Commercial Companies Code, carried outby way of a public offering exempt from the obligation to publish aprospectus within the meaning of the relevant provisions of law oranother information or offering document for the purpose of such anoffering, and in particular that the selection of investors to whomoffers to subscribe for U series shares is made with account taken ofthe book-building process or another process aimed at acquiring entitiessubscribing for new issue shares. In the opinion of the Management Boardof the Company, the issue of U series shares should be carried out withthe full exclusion of the existing shareholders' pre-emptive right toall U series shares, which is in the interest of the Company and itsshareholders and serves to ensure efficient provision of its capital.The issue price of U series shares will be determined by the ManagementBoard of the Company within the limits set by the General Meeting.

The Company will inform about convening the OrdinaryGeneral Meeting providing for the adoption of a resolution on increasingthe Company's share capital through the issue of ordinary bearer sharesof U series by means of a separate current report, in accordance withthe applicable regulations.